Point72 Asia (Singapore) Pte. Ltd. Reneo Pharmaceuticals, Inc. Call Options Transaction History
Point72 Asia (Singapore) Pte. Ltd.
- $532 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RPHM
# of Institutions
53Shares Held
31MCall Options Held
50.8KPut Options Held
0-
Nea Management Company, LLC Timonium, MD4.79MShares$8.04 Million0.62% of portfolio
-
Bml Capital Management, LLC Zionsville, IN3.46MShares$5.81 Million3.46% of portfolio
-
Highbridge Capital Management LLC New York, NY3.06MShares$5.15 Million1.56% of portfolio
-
Tang Capital Management LLC San Diego, CA2.95MShares$4.95 Million0.43% of portfolio
-
Carlyle Group Inc. Washington, DC2.7MShares$4.53 Million0.69% of portfolio
About Reneo Pharmaceuticals, Inc.
- Ticker RPHM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,479,600
- Market Cap $41.1M
- Description
- Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...